Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites.
Neoplasms of the bony part of the skull.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Abnormal immunoglobulins synthesized by atypical cells of the MONONUCLEAR PHAGOCYTE SYSTEM. Paraproteins containing only light chains lead to Bence Jones paraproteinemia, while the presence of only atypical heavy chains leads to heavy chain disease. Most of the paraproteins show themselves as an M-component (monoclonal gammopathy) in electrophoresis. Diclonal and polyclonal paraproteins are much less frequently encountered.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
Inbred BALB/c mice are a strain of laboratory mice that have been selectively bred to be genetically identical to each other, making them useful for scientific research and experiments due to their consistent genetic background and predictable responses to various stimuli or treatments.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
One of the types of light chains of the immunoglobulins with a molecular weight of approximately 22 kDa.
Conditions characterized by the presence of M protein (Monoclonal protein) in serum or urine without clinical manifestations of plasma cell dyscrasia.
One of the types of light chain subunits of the immunoglobulins with a molecular weight of approximately 22 kDa.
A mixture of liquid hydrocarbons obtained from petroleum. It is used as laxative, lubricant, ointment base, and emollient.
A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.
Tumors or cancer of the MAXILLARY SINUS. They represent the majority of paranasal neoplasms.
Tumors or cancer located in bone tissue or specific BONES.
A multisystemic disorder characterized by a sensorimotor polyneuropathy (POLYNEUROPATHIES), organomegaly, endocrinopathy, monoclonal gammopathy, and pigmentary skin changes. Other clinical features which may be present include EDEMA; CACHEXIA; microangiopathic glomerulopathy; pulmonary hypertension (HYPERTENSION, PULMONARY); cutaneous necrosis; THROMBOCYTOSIS; and POLYCYTHEMIA. This disorder is frequently associated with osteosclerotic myeloma. (From Adams et al., Principles of Neurology, 6th ed, p1335; Rev Med Interne 1997;18(7):553-62)
Respiratory Tract Neoplasms are defined as abnormal growths or tumors that develop within the respiratory system, including the nose, sinuses, throat (pharynx), voice box (larynx), windpipe (trachea), bronchi, and lungs, which can be benign or malignant, with the potential to cause significant morbidity and mortality.
The class of heavy chains found in IMMUNOGLOBULIN D. They have a molecular weight of approximately 64 kDa and they contain about 500 amino acid residues arranged in four domains and an oligosaccharide component covalently bound to the Fc fragment constant region.
Genes and gene segments encoding the IMMUNOGLOBULIN LIGHT CHAINS. Gene segments of the light chain genes are designated as V (variable), J (joining), and C (constant).
Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.
The class of heavy chains found in IMMUNOGLOBULIN M. They have a molecular weight of approximately 72 kDa and they contain about 57 amino acid residues arranged in five domains and have more oligosaccharide branches and a higher carbohydrate content than the heavy chains of IMMUNOGLOBULIN G.
A class of compounds composed of repeating 5-carbon units of HEMITERPENES.
The class of heavy chains found in IMMUNOGLOBULIN A. They have a molecular weight of approximately 58 kDa and contain about 470 amino acid residues arranged in four domains and an oligosaccharide component bound covalently to their Fc fragment constant region.
The largest of three bones that make up each half of the pelvic girdle.
A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.

The requirement of an adherent cell substratum for the growth of developing plasmacytoma cells in vivo. (1/1022)

The intraperitoneal injection of pristane (2,6,10,14-tetramethylpentadecane) produces an environment conductive to primary plasmacytoma growth in as few as 3 days. After pristane injection, the total free peritoneal cell population increases from a normal value of 1.55 X 10(6) to 5.28 X 10(6) and remains at this elevated level for at least 50 days. The adherent peritoneal cell population, composed of both mononuclear cells and polymorphonuclear leukocytes, is the primary source of this increase. In the pristane-conditioned peritoneum, these cells rapidly form a chronic granuloma on the peritoneal connective tissues. Daily subcutaneous treatment of mice with 0.5 mg of hydrocortisone beginning simultaneously with pristane injection prevents the increase in the peritoneal cell population, granuloma formation, d the production of a conditoned environment. In mice treated with hydrocortisone beginning 3 days after pristane injection, however, neither the peritoneal cell increase nor the production of a conditioned environment is prevented. The intraperitoneal injection of thioglycolate medium at 4-day intervals produces an elevation of the free adherent peritoneal cell population similar to pristane, but does not produce a granuloma or a conditioned environment. The intraperitoneal transfer of thioglycolate-induced adherent peritonel cells to mice treated with pristane and hydrocortisone simultaneously restores the production of a conditioned environment. These findings indicate that the adherent peritoneal cell population is responsible for the conditioning effect, and that the establishment of a resident population of these cells is necessary to produce conditioning.  (+info)

Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. (2/1022)

Transplantation after high-dose chemotherapy prolongs survival in patients with multiple myeloma compared with standard therapy. It is unclear whether the optimal timing of transplantation is immediately after induction chemotherapy or whether stem cells may be cryopreserved for transplantation at subsequent progression or relapse. In this study, stem cells were collected within 6 months of diagnosis, followed by transplantation only at progression of myeloma. One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved. Eleven had transplants early in the disease after they demonstrated failure to respond to primary therapy. The remaining 107 were eligible for transplants when there was evidence of progressive disease. Of the 118 patients, 67 had transplants, nine died of progressive disease before transplantation, and 42 remain alive in plateau phase. The median survival of the group is 58.5 months; 67 are alive. Serum beta2-microglobulin, bone marrow labeling index (S phase), and hemoglobin level predicted overall survival (P < 0.006, P < 0.001, and P < 0.01, respectively). We conclude that early cryopreservation of blood stem cells followed by transplantation at progression is a feasible approach to therapy in patients with myeloma. The underlying biology of the disease has a greater impact on survival than the timing of transplantation. A prospective randomized trial is required to answer definitively the question of the optimal timing of blood cell transplantation.  (+info)

Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy. (3/1022)

BACKGROUND AND OBJECTIVE: The tracer tachnetium-99m-2-methoxy-isobutyl-isonitrile (Tc99m-sestaMIBI) has recently been shown to concentrate in some neoplastic tissues, including myeloma. We investigated the diagnostic capacity and limits of this procedure in tracing focal myeloma lesions, and compared them with those of conventional radiological procedures (Xr). DESIGN AND METHODS: We studied 55 patients suffering from multiple myeloma (MM) or solitary plasmacytoma in different stages and clinical conditions, or from monoclonal gammopathy of undefined significance (MGUS), by whole body scans obtained 10 minutes after injection of 555 MBq of Tc99m-sestaMIBI. Scans were defined as normal (physiological uptake only), diffuse (presence of bone marrow uptake), or focal (localized areas of uptake), and were compared to conventional skeletal Xr. RESULTS: Thirty patients showed no focal areas of Tc99m-sestaMIBI uptake; this group consisted of 5 patients with MGUS, 6 with MM in stage IA and 2 in stage IIA, 11 patients studied after effective chemotherapy and 6 in early relapse. Twenty-five patients showed one or more spots of focal uptake: all of them had active disease (untreated, resistant or relapsing MM). In the setting of tracing focal lesions, Tc99m-sestaMIBI scans were concordant with the radiological examination in 38 patients and discordant in 17. Among the latter, in 4 cases Tc99m-sestaMIBI revealed focal lesions not detected by Xr, and in 13 cases lytic areas detected by Xr did not show Tc99m-sestaMIBI uptake. INTERPRETATION AND CONCLUSIONS: In untreated patients, the number of lesions revealed by Tc99m-sestaMIBI was comparable to that shown by Xr, while in pretreated patients Tc99m-sestaMIBI traced a number of lesions lower than that detected by Xr. The reason for this discrepancy is that Tc99m-sestaMIBI traces only active lesions. Tc99m-sestaMIBI limitations in identifying focal lesions may derive from the dimension of the smallest traceable lesion (about one centimeter), and from the possibility that focal plasma cell localizations in collapsed bone may not be visualized due to inadequate vascularization. Tc99m-sestaMIBI scintigraphy is an interesting tool for diagnosing, staging and following up focal myeloma lesions, in the bone as well as in soft tissues. It is more specific than conventional Xr in identifying sites of active disease.  (+info)

Genetic control of resistance to tumors. (4/1022)

Hybrid resistance to a BALB/c plasmacytoma, MPC-11, has been investigated. The results indicate that heterozygosity within the H-2 complex is neither necessary nor sufficient for resistance to be observed. However, in the presence of a single gene or gene complex which segregates independently of H-2, differential effects of various H-2 haplotypes can be seen. Resistance is radiation-sensitive and silica-insensitive and probably depends on active immune responses. The data also suggest that production by a hybrid of endogenous viral antigens with certain type-specific determinants shared with viral antigens expressed on the tumor may interfere with resistance. The mechanism for this is not understood but might involve tolerance, suppression, or enhancing antibody.  (+info)

Tumor-induced immunosuppression. (5/1022)

Three tumor systems, including a mastocytoma, plasmacytomas, and a leukemia-lymphoma were studied for their ability to modify humoral immunity to sheep erythrocytes both in vivo and in vitro. All tumors resulted in a depression of the hemolytic antibody plaque-forming cell response in susceptible mice. These studies indicated that the mechanism(s) of suppression, although not fully defined, were different for each model system investigated.  (+info)

Murine plasmacytomas, carrier of the t(12;15) chromosomal translocation, develop from immature/mature B cells not from differentiated plasma cells. (6/1022)

Dysregulation of the c-myc gene by chromosomal translocation in >95% of murine plasmacytomas (MPCs) is an obligatory requirement for the transformation of B lymphocytes into MPCs. However, it is still unknown whether sIg+ B cells or differentiated plasma cells are the legitimate precursor cells from which MPCs develop. To address this question, C.B-17 scid/scid (SCID) mice were reconstituted with splenic surface Ig-positive (sIg+) B lineage cells originating from BALB/cRb6.15 (B/cRb6.15) or human IL-6 transgene-congenic BALB/cRb8.12 mice (B/cRb8.12 IL-6-Tg). Six of 80 SCID mice reconstituted with B/cRb6.15 sIg+ B cells developed MPCs after pristane (2,6,10,14-tetramethylpentadecane) treatment followed by Abelson murine leukemia virus (A-MuLV) infection (incidence 7.5%) and four of 40 after pristane treatment alone (incidence 10%). Similarly, in 20 SCID mice reconstituted with B/cRb8.12 IL-6-Tg splenic sIg+ B cells the MPC incidence was 10%. Karyotype analysis revealed that all the translocations were of typical t(12;15) type and all tumors carried the Rb6.15 or Rb8.12 marker chromosome, indicating their donor cell origin. In contrast, none of the 48 SCID mice reconstituted with plasma cells obtained from the lymph nodes of B/cRb8.12 IL-6-Tg mice developed MPCs when treated either with pristane plus A-MuLV (20 mice) or with pristane alone (28 mice), although the transferred plasma cells were still functional in the recipient SCID mice 6 months after transfer. The findings indicate that the malignant transformation triggered by Ig/myc juxtaposition occurs more in immature (sIgM+) and/or mature (sIgM+/sIgD+, sIgG+ and sIgA+) B cells than in differentiated G0 or cycling plasma cells. We inferred that immature and/or mature B cells and not differentiated plasma cells are most likely the principal source of precursor cells from which the typical t(12;15) MPCs develop.  (+info)

BALB/c.CBA/N mice carrying the defective Btk(xid) gene are resistant to pristane-induced plasmacytomagenesis. (7/1022)

The X-chromosome from the CBA/N mouse which carries the defective Bruton's tyrosine kinase (Btk) allele (Xxid) has been introgressively backcrossed onto the plasmacytoma (PCT) induction-susceptible BALB/cAN. Inbred BALB/c.CBA/N-xid/xid (C.CBA/N) mice raised and maintained in our conventional colony were given three 0.5 ml injections of pristane and were highly refractory to PCT induction. Only one PCT was found among 59 mice followed for > or =300 days. Twenty mice were examined at day 200 for foci of plasma cells in the oil granuloma. Ten mice had small foci of plasma cells, most of which were plasmacytotic, embedded in the inflammatory oil granuloma. In one there were multiple foci, but most of the mice had only one or two foci. F1 hybrid XxidY males derived from CBA/N females crossed to BALB/cAnPt were also resistant to PCT induction, while heterozygous and homozygous XY males were susceptible. C.CBA/N mice can develop extensive mucosal plasma cells as well as plasma cell accumulations in oil granuloma tissue, but the precursors of these plasma cells do not give rise to PCT in genetically susceptible hosts. The failure of C.CBA/N mice to develop PCT is probably due to the elimination of B cell clones that can be perpetuated by repeated exposure to thymus-independent type 2 antigens.  (+info)

Mistletoe lectin dissociates into catalytic and binding subunits before translocation across the membrane to the cytoplasm. (8/1022)

Hybridomas producing monoclonal antibodies (mAbs) against the mistletoe lectin A-chain (MLA) were obtained to investigate the intracellular routing and translocation of ribosome-inactivating proteins. Anti-MLA mAb MNA5 did not bind the holotoxin but interacted with isolated MLA. This epitope was not recognized upon MLA denaturation or conjugation of MLA with the ricin binding subunit (RTB). Furthermore, the mAbs did not appreciably react with a panel of MLA synthetic octapeptides linked to the surface of polyethylene pins. A study of the cytotoxicity of mistletoe lectin, ricin, and chimeric toxin MLA/RTB for the hybridomas revealed that interchain disulfide bond reduction and subunit dissociation are required for cytotoxic activity of mistletoe lectin.  (+info)

A plasmacytoma is a discrete tumor mass that is composed of neoplastic plasma cells, which are a type of white blood cell found in the bone marrow. Plasmacytomas can be solitary (a single tumor) or multiple (many tumors), and they can develop in various locations throughout the body.

Solitary plasmacytoma is a rare cancer that typically affects older adults, and it usually involves a single bone lesion, most commonly found in the vertebrae, ribs, or pelvis. In some cases, solitary plasmacytomas can also occur outside of the bone (extramedullary plasmacytoma), which can affect soft tissues such as the upper respiratory tract, gastrointestinal tract, or skin.

Multiple myeloma is a more common and aggressive cancer that involves multiple plasmacytomas in the bone marrow, leading to the replacement of normal bone marrow cells with malignant plasma cells. This can result in various symptoms such as bone pain, anemia, infections, and kidney damage.

The diagnosis of plasmacytoma typically involves a combination of imaging studies, biopsy, and laboratory tests to assess the extent of the disease and determine the appropriate treatment plan. Treatment options for solitary plasmacytoma may include surgery or radiation therapy, while multiple myeloma is usually treated with chemotherapy, targeted therapy, immunotherapy, and/or stem cell transplantation.

Skull neoplasms refer to abnormal growths or tumors that develop within the skull. These growths can be benign (non-cancerous) or malignant (cancerous). They can originate from various types of cells, such as bone cells, nerve cells, or soft tissues. Skull neoplasms can cause various symptoms depending on their size and location, including headaches, seizures, vision problems, hearing loss, and neurological deficits. Treatment options include surgery, radiation therapy, and chemotherapy. It is important to note that a neoplasm in the skull can also refer to metastatic cancer, which has spread from another part of the body to the skull.

Multiple myeloma is a type of cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help your body fight infection by producing antibodies. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Rather than producing useful antibodies, the cancer cells produce abnormal proteins that can cause complications such as kidney damage, bone pain and fractures.

Multiple myeloma is a type of cancer called a plasma cell neoplasm. Plasma cell neoplasms are diseases in which there is an overproduction of a single clone of plasma cells. In multiple myeloma, this results in the crowding out of normal plasma cells, red and white blood cells and platelets, leading to many of the complications associated with the disease.

The abnormal proteins produced by the cancer cells can also cause damage to organs and tissues in the body. These abnormal proteins can be detected in the blood or urine and are often used to monitor the progression of multiple myeloma.

Multiple myeloma is a relatively uncommon cancer, but it is the second most common blood cancer after non-Hodgkin lymphoma. It typically occurs in people over the age of 65, and men are more likely to develop multiple myeloma than women. While there is no cure for multiple myeloma, treatments such as chemotherapy, radiation therapy, and stem cell transplantation can help manage the disease and its symptoms, and improve quality of life.

Myeloma proteins, also known as monoclonal immunoglobulins or M-proteins, are entire or abnormal immunoglobulin (antibody) molecules produced by a single clone of plasma cells, which are malignant in the case of multiple myeloma and some related disorders. These proteins accumulate in the blood and/or urine and can cause damage to various organs and tissues.

In multiple myeloma, the excessive proliferation of these plasma cells leads to the overproduction of a single type of immunoglobulin or its fragments, which can be detected and quantified in serum and/or urine electrophoresis. The most common types of myeloma proteins are IgG and IgA, followed by light chains (Bence Jones proteins) and, less frequently, IgD and IgM.

The presence and levels of myeloma proteins are important diagnostic markers for multiple myeloma and related disorders, such as monoclonal gammopathy of undetermined significance (MGUS) and Waldenström macroglobulinemia. Regular monitoring of these proteins helps assess the disease's activity, response to treatment, and potential complications like kidney dysfunction or amyloidosis.

Plasma cell neoplasms are a type of cancer that originates from plasma cells, which are a type of white blood cell found in the bone marrow. These cells are responsible for producing antibodies to help fight off infections. When plasma cells become cancerous and multiply out of control, they can form a tumor called a plasmacytoma.

There are two main types of plasma cell neoplasms: solitary plasmacytoma and multiple myeloma. Solitary plasmacytoma is a localized tumor that typically forms in the bone, while multiple myeloma is a systemic disease that affects multiple bones and can cause a variety of symptoms such as bone pain, fatigue, and anemia.

Plasma cell neoplasms are diagnosed through a combination of tests, including blood tests, imaging studies, and bone marrow biopsy. Treatment options depend on the stage and extent of the disease, but may include radiation therapy, chemotherapy, and stem cell transplantation.

Paraproteins, also known as M-proteins or monoclonal proteins, are immunoglobulins (antibodies) that are produced in abnormal amounts by a single clone of plasma cells. These proteins are typically produced in response to a stimulus such as an infection, but when they are produced in excessive and/or unusual forms, it can indicate the presence of a clonal disorder, such as multiple myeloma, Waldenstrom macroglobulinemia, or other related conditions.

Paraproteins can be detected in the blood or urine and are often used as a marker for disease progression and response to treatment. They can also cause various symptoms and complications, depending on their size, concentration, and location. These may include damage to organs such as the kidneys, nerves, and bones.

Immunoglobulin heavy chains are proteins that make up the framework of antibodies, which are Y-shaped immune proteins. These heavy chains, along with light chains, form the antigen-binding sites of an antibody, which recognize and bind to specific foreign substances (antigens) in order to neutralize or remove them from the body.

The heavy chain is composed of a variable region, which contains the antigen-binding site, and constant regions that determine the class and function of the antibody. There are five classes of immunoglobulins (IgA, IgD, IgE, IgG, and IgM) that differ in their heavy chain constant regions and therefore have different functions in the immune response.

Immunoglobulin heavy chains are synthesized by B cells, a type of white blood cell involved in the adaptive immune response. The genetic rearrangement of immunoglobulin heavy chain genes during B cell development results in the production of a vast array of different antibodies with unique antigen-binding sites, allowing for the recognition and elimination of a wide variety of pathogens.

BALB/c is an inbred strain of laboratory mouse that is widely used in biomedical research. The strain was developed at the Institute of Cancer Research in London by Henry Baldwin and his colleagues in the 1920s, and it has since become one of the most commonly used inbred strains in the world.

BALB/c mice are characterized by their black coat color, which is determined by a recessive allele at the tyrosinase locus. They are also known for their docile and friendly temperament, making them easy to handle and work with in the laboratory.

One of the key features of BALB/c mice that makes them useful for research is their susceptibility to certain types of tumors and immune responses. For example, they are highly susceptible to developing mammary tumors, which can be induced by chemical carcinogens or viral infection. They also have a strong Th2-biased immune response, which makes them useful models for studying allergic diseases and asthma.

BALB/c mice are also commonly used in studies of genetics, neuroscience, behavior, and infectious diseases. Because they are an inbred strain, they have a uniform genetic background, which makes it easier to control for genetic factors in experiments. Additionally, because they have been bred in the laboratory for many generations, they are highly standardized and reproducible, making them ideal subjects for scientific research.

Experimental neoplasms refer to abnormal growths or tumors that are induced and studied in a controlled laboratory setting, typically in animals or cell cultures. These studies are conducted to understand the fundamental mechanisms of cancer development, progression, and potential treatment strategies. By manipulating various factors such as genetic mutations, environmental exposures, and pharmacological interventions, researchers can gain valuable insights into the complex processes underlying neoplasm formation and identify novel targets for cancer therapy. It is important to note that experimental neoplasms may not always accurately represent human cancers, and further research is needed to translate these findings into clinically relevant applications.

Immunoglobulin kappa-chains are one of the two types of light chains (the other being lambda-chains) that make up an immunoglobulin molecule, also known as an antibody. These light chains combine with heavy chains to form the antigen-binding site of an antibody, which is responsible for recognizing and binding to specific antigens or foreign substances in the body.

Kappa-chains contain a variable region that differs between different antibodies and contributes to the diversity of the immune system's response to various antigens. They also have a constant region, which is consistent across all kappa-chains. Approximately 60% of all human antibodies contain kappa-chains, while the remaining 40% contain lambda-chains. The relative proportions of kappa and lambda chains can be used in diagnostic tests to identify clonal expansions of B cells, which may indicate a malignancy such as multiple myeloma or lymphoma.

Monoclonal gammopathy of undetermined significance (MGUS) is a medical condition characterized by the presence of a monoclonal protein, or M-protein, in the blood or urine, but without any signs or symptoms of related disorders. The M-protein is produced by a single clone of plasma cells, which are a type of white blood cell found in the bone marrow.

In MGUS, the level of M-protein is typically low (less than 3 grams per deciliter), and there are no signs of damage to organs such as the bones, kidneys, or nervous system. However, people with MGUS have a higher risk of developing certain related conditions, such as multiple myeloma, amyloidosis, or lymphoplasmacytic lymphoma, compared to those without MGUP.

MGUS is usually detected through routine blood or urine tests and is typically asymptomatic. However, in some cases, people with MGUS may experience symptoms such as fatigue, bone pain, or recurrent infections. If these symptoms occur, further testing may be necessary to determine if MGUS has progressed to a more serious condition.

It's important to note that MGUS is not a cancer itself, but rather a potential precursor to certain types of cancer. Regular monitoring with blood or urine tests and physical examinations is recommended for people diagnosed with MGUS to monitor for any changes that may indicate progression to a more serious condition.

Immunoglobulin lambda-chains (Igλ) are one type of light chain found in the immunoglobulins, also known as antibodies. Antibodies are proteins that play a crucial role in the immune system's response to foreign substances, such as bacteria and viruses.

Immunoglobulins are composed of two heavy chains and two light chains, which are interconnected by disulfide bonds. There are two types of light chains: kappa (κ) and lambda (λ). Igλ chains are one type of light chain that can be found in association with heavy chains to form functional antibodies.

Igλ chains contain a variable region, which is responsible for recognizing and binding to specific antigens, and a constant region, which determines the class of the immunoglobulin (e.g., IgA, IgD, IgE, IgG, or IgM).

In humans, approximately 60% of all antibodies contain Igλ chains, while the remaining 40% contain Igκ chains. The ratio of Igλ to Igκ chains can vary depending on the type of immunoglobulin and its function in the immune response.

Medical Definition of Mineral Oil:

Mineral oil is a commonly used laxative, which is a substance that promotes bowel movements. It is a non-digestible, odorless, and tasteless oil that is derived from petroleum. When taken orally, mineral oil passes through the digestive system without being absorbed, helping to soften stools and relieve constipation by increasing the weight and size of the stool, stimulating the reflexes in the intestines that trigger bowel movements.

Mineral oil is also used topically as a moisturizer and emollient for dry skin conditions such as eczema and dermatitis. It forms a barrier on the skin, preventing moisture loss and protecting the skin from irritants. However, mineral oil should not be used on broken or inflamed skin, as it can trap bacteria and delay healing.

It is important to note that long-term use of mineral oil laxatives can lead to dependence and may interfere with the absorption of fat-soluble vitamins such as A, D, E, and K. Therefore, it should be used only under the guidance of a healthcare professional.

Paraproteinemias refer to the presence of abnormal levels of paraproteins in the blood. Paraproteins are immunoglobulins (antibodies) produced by plasma cells, which are a type of white blood cell found in the bone marrow. In healthy individuals, paraproteins play a role in the immune system's response to infection and disease. However, in certain conditions, such as multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), and Waldenstrom macroglobulinemia, plasma cells produce excessive amounts of a single type of paraprotein, leading to its accumulation in the blood.

Paraproteinemias can cause various symptoms depending on the level of paraproteins present and their impact on organs and tissues. These symptoms may include fatigue, weakness, numbness or tingling in the extremities, bone pain, recurrent infections, and kidney problems. In some cases, paraproteinemias may not cause any symptoms and may only be detected during routine blood tests.

It is important to note that while paraproteinemias are often associated with plasma cell disorders, they can also occur in other conditions such as chronic inflammation or autoimmune diseases. Therefore, further testing and evaluation are necessary to determine the underlying cause of paraproteinemia and develop an appropriate treatment plan.

Maxillary sinus neoplasms refer to abnormal growths or tumors that develop in the maxillary sinuses, which are located in the upper part of your cheekbones, below your eyes. These growths can be benign (non-cancerous) or malignant (cancerous).

Benign neoplasms may include conditions such as an osteoma (a benign bone tumor), a papilloma (a benign growth of the lining of the sinus), or a fibrous dysplasia (a condition where bone is replaced by fibrous tissue).

Malignant neoplasms, on the other hand, can be primary (originating in the maxillary sinuses) or secondary (spreading to the maxillary sinuses from another site in the body). Common types of malignant tumors that arise in the maxillary sinus include squamous cell carcinoma, adenocarcinoma, and mucoepidermoid carcinoma.

Symptoms of maxillary sinus neoplasms may include nasal congestion, nosebleeds, facial pain or numbness, vision changes, and difficulty swallowing or speaking. Treatment options depend on the type, size, and location of the tumor but may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Bone neoplasms are abnormal growths or tumors that develop in the bone. They can be benign (non-cancerous) or malignant (cancerous). Benign bone neoplasms do not spread to other parts of the body and are rarely a threat to life, although they may cause problems if they grow large enough to press on surrounding tissues or cause fractures. Malignant bone neoplasms, on the other hand, can invade and destroy nearby tissue and may spread (metastasize) to other parts of the body.

There are many different types of bone neoplasms, including:

1. Osteochondroma - a benign tumor that develops from cartilage and bone
2. Enchondroma - a benign tumor that forms in the cartilage that lines the inside of the bones
3. Chondrosarcoma - a malignant tumor that develops from cartilage
4. Osteosarcoma - a malignant tumor that develops from bone cells
5. Ewing sarcoma - a malignant tumor that develops in the bones or soft tissues around the bones
6. Giant cell tumor of bone - a benign or occasionally malignant tumor that develops from bone tissue
7. Fibrosarcoma - a malignant tumor that develops from fibrous tissue in the bone

The symptoms of bone neoplasms vary depending on the type, size, and location of the tumor. They may include pain, swelling, stiffness, fractures, or limited mobility. Treatment options depend on the type and stage of the tumor but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

POEMS syndrome is a rare and complex disorder that affects multiple parts of the body. The name POEMS is an acronym that stands for the following symptoms: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes.

Here's a brief definition of each component of the syndrome:

* Polyneuropathy: This refers to damage to the peripheral nerves that can cause symptoms such as numbness, tingling, pain, and weakness in the arms and legs.
* Organomegaly: This means enlargement of organs, such as the liver, spleen, or lymph nodes.
* Endocrinopathy: This refers to abnormalities in hormone-producing glands, which can lead to symptoms such as diabetes, low testosterone levels, and thyroid dysfunction.
* Monoclonal gammopathy: This is an abnormal production of a single type of immunoglobulin (a protein produced by the immune system) in the bone marrow.
* Skin changes: These can include skin thickening, darkening, or redness, as well as skin lesions.

POEMS syndrome is typically caused by an underlying plasma cell disorder, such as multiple myeloma or a related condition called Waldenstrom macroglobulinemia. Treatment for POEMS syndrome usually involves addressing the underlying plasma cell disorder, as well as managing specific symptoms of the syndrome.

Respiratory tract neoplasms refer to abnormal growths or tumors that occur in the respiratory system, which includes the nose, throat (pharynx), voice box (larynx), windpipe (trachea), bronchi, and lungs. These growths can be benign or malignant (cancerous). Malignant neoplasms are cancerous tumors that can invade nearby tissues, spread to other parts of the body, and interfere with normal respiratory function, leading to serious health consequences.

Respiratory tract neoplasms can have various causes, including genetic factors, exposure to environmental carcinogens such as tobacco smoke, asbestos, and radon, and certain viral infections. Symptoms of respiratory tract neoplasms may include coughing, wheezing, shortness of breath, chest pain, hoarseness, or blood in the sputum. Diagnosis typically involves imaging tests such as X-rays, CT scans, or PET scans, as well as biopsies to determine the type and extent of the tumor. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

Immunoglobulin delta-chains (IgD) are a type of heavy chain found in immunoglobulins, which are also known as antibodies. Antibodies are proteins that play a crucial role in the immune system's response to foreign substances, such as bacteria and viruses.

The heavy chains of an antibody consist of four polypeptide regions: the variable region, which varies between different antibodies and is responsible for recognizing and binding to specific antigens; and three constant regions, known as Cμ, Cγ, Cα, or Cδ, which determine the class of the antibody and its effector functions.

IgD heavy chains contain a single Cδ region and are found only in a small subset of antibodies, primarily located on the surface of mature B cells. IgD is co-expressed with IgM on the surface of naive B cells and plays a role in activating the immune response by binding to antigens and initiating signal transduction pathways that lead to B cell activation and differentiation into antibody-secreting plasma cells.

While the function of IgD is not fully understood, it is thought to play a role in regulating the immune response, including modulating allergic reactions and protecting against autoimmunity. Additionally, IgD has been found to have a role in the development and survival of B cells, as well as in the regulation of calcium signaling in B cells.

Immunoglobulin light chains are proteins that play a crucial role in the immune system's response to foreign substances. They are called "light chains" because they are smaller than the heavy chains that make up the other part of an antibody molecule.

There are two types of light chains, known as kappa (κ) and lambda (λ) chains, which are produced by genes located on chromosomes 2 and 22, respectively. Each immunoglobulin molecule contains either two kappa or two lambda light chains, in addition to two heavy chains.

The genes that code for light chains undergo a process called V(D)J recombination during the development of B cells, which allows for the generation of a diverse repertoire of antibodies with different specificities. This process involves the selection and rearrangement of various gene segments to create a unique immunoglobulin light chain protein.

Defects in the genes that code for immunoglobulin light chains can lead to various immune disorders, such as immunodeficiencies or autoimmune diseases. Additionally, abnormal light chain proteins can accumulate in the body and form amyloid fibrils, leading to a condition called light chain amyloidosis.

Immunoglobulin light chains are the smaller protein subunits of an immunoglobulin, also known as an antibody. They are composed of two polypeptide chains, called kappa (κ) and lambda (λ), which are produced by B cells during the immune response. Each immunoglobulin molecule contains either two kappa or two lambda light chains, in association with two heavy chains.

Light chains play a crucial role in the antigen-binding site of an antibody, where they contribute to the specificity and affinity of the interaction between the antibody and its target antigen. In addition to their role in immune function, abnormal production or accumulation of light chains can lead to various diseases, such as multiple myeloma and amyloidosis.

Immunoglobulin mu-chains (IgM) are a type of heavy chain found in immunoglobulins, also known as antibodies. IgM is the first antibody to be produced in response to an initial exposure to an antigen and plays a crucial role in the early stages of the immune response.

IgM antibodies are composed of four monomeric units, each consisting of two heavy chains and two light chains. The heavy chains in IgM are called mu-chains, which have a molecular weight of approximately 72 kDa. Each mu-chain contains five domains: one variable (V) domain at the N-terminus, four constant (C) domains (Cμ1-4), and a membrane-spanning region followed by a short cytoplasmic tail.

IgM antibodies are primarily found on the surface of B cells as part of the B cell receptor (BCR). When a B cell encounters an antigen, the BCR binds to it, triggering a series of intracellular signaling events that lead to B cell activation and differentiation into plasma cells. In response to activation, the B cell begins to secrete IgM antibodies into the bloodstream.

IgM antibodies have several unique features that make them effective in the early stages of an immune response. They are highly efficient at agglutination, or clumping together, of pathogens and antigens, which helps to neutralize them. IgM antibodies also activate the complement system, a group of proteins that work together to destroy pathogens.

Overall, Immunoglobulin mu-chains are an essential component of the immune system, providing early protection against pathogens and initiating the adaptive immune response.

Terpenes are a large and diverse class of organic compounds produced by a variety of plants, including cannabis. They are responsible for the distinctive aromas and flavors found in different strains of cannabis. Terpenes have been found to have various therapeutic benefits, such as anti-inflammatory, analgesic, and antimicrobial properties. Some terpenes may also enhance the psychoactive effects of THC, the main psychoactive compound in cannabis. It's important to note that more research is needed to fully understand the potential medical benefits and risks associated with terpenes.

Immunoglobulin alpha-chains (IgA) are a type of immunoglobulin or antibody that plays a crucial role in the immune system. They are composed of two heavy chains, known as alpha-chains, and two light chains. IgA is primarily found in secretions such as tears, saliva, breast milk, and respiratory and intestinal mucus, where they provide protection against pathogens that enter the body through these surfaces.

IgA can exist in two forms: a monomeric form, which consists of a single IgA molecule, and a polymeric form, which consists of several IgA molecules joined together by a J chain. The polymeric form is more common in secretions, where it provides an effective barrier against pathogens.

IgA functions by binding to antigens on the surface of pathogens, preventing them from attaching to and infecting host cells. It can also neutralize toxins produced by some bacteria and viruses. Additionally, IgA can activate the complement system, a group of proteins that work together to destroy pathogens, and initiate an immune response by recruiting other immune cells to the site of infection.

Deficiencies in IgA are relatively common and usually do not cause any significant health problems. However, in some cases, people with IgA deficiency may develop recurrent infections or allergies.

The ilium is the largest and broadest of the three parts that make up the hip bone or coxal bone. It is the uppermost portion of the pelvis and forms the side of the waist. The ilium has a curved, fan-like shape and articulates with the sacrum at the back to form the sacroiliac joint. The large, concave surface on the top of the ilium is called the iliac crest, which can be felt as a prominent ridge extending from the front of the hip to the lower back. This region is significant in orthopedics and physical examinations for its use in assessing various medical conditions and performing certain maneuvers during the physical examination.

Translocation, genetic, refers to a type of chromosomal abnormality in which a segment of a chromosome is transferred from one chromosome to another, resulting in an altered genome. This can occur between two non-homologous chromosomes (non-reciprocal translocation) or between two homologous chromosomes (reciprocal translocation). Genetic translocations can lead to various clinical consequences, depending on the genes involved and the location of the translocation. Some translocations may result in no apparent effects, while others can cause developmental abnormalities, cancer, or other genetic disorders. In some cases, translocations can also increase the risk of having offspring with genetic conditions.

"Guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary ... The International Myeloma Working Group lists three types: solitary plasmacytoma of bone (SPB); extramedullary plasmacytoma (EP ... "solitary plasmacytoma". or as part of the phrase "extramedullary plasmacytoma". In this context, "extramedullary" means outside ... 1 ratio for extramedullary plasmacytoma. There can be some ambiguity when using the word. "Plasmacytoma" is sometimes equated ...
While its presentations and findings are similar to solitary plasmacytoma, solitary plasmacytoma with minimal bone marrow ... Solitary plasmacytoma is a rare disease with an incidence in the USA of ~1.6% but less than 10% of total nucleated cells. ... Solitary plasmacytoma is an early stage malignancy with a clinical course that lies between MGUS and multiple myeloma in the ... Thumallapally N, Meshref A, Mousa M, Terjanian T (2017). "Solitary plasmacytoma: population-based analysis of survival trends ...
"Extramedullary plasmacytoma confined to the choroid". Am J Ophthalmol. 131 (2): 277-8. doi:10.1016/s0002-9394(00)00706-6. PMID ...
Mock BA, Connelly MA, McBride OW, Kozak CA, Marcu KB (Feb 1997). "Plasmacytoma-associated neuronal glycoprotein, Pang, maps to ... "Entrez Gene: CNTN3 contactin 3 (plasmacytoma associated)". Human CNTN3 genome location and CNTN3 gene details page in the UCSC ...
Cytokine network imbalances in plasmacytoma - regressor mice. Curr Top Microbiol Immunol. 246:395-401. 1999. Ran M, Langer AB, ...
"Alpha-chain disease with localized plasmacytoma of the intestine. Immunoperoxidase study". Clinical and Experimental Immunology ...
Hughes M, Soutar R, Lucraft H, Owen R, Bird J. "Guidelines on the diagnosis and management of solitary plasmacytoma of bone, ... September 2006). "Immunoglobulin free light chains and solitary plasmacytoma of bone". Blood. 108 (6): 1979-83. doi:10.1182/ ... plasmacytoma and the comparison of treatment responses in clinical trials have also been published. Technical and clinical ... smouldering myeloma and solitary plasmacytoma of the bone. Abnormal free light chain production has also been reported to be ...
Yan J, Wang J, Zhang W, Chen M, Chen J, Liu W (April 2017). "Solitary plasmacytoma associated with Epstein-Barr virus: a ... When one tumor is present, it is called a plasmacytoma; more than one is called multiple myeloma. Multiple myeloma is diagnosed ... 10% on bone marrow biopsy or (in any quantity) in a biopsy from other tissues (plasmacytoma) A monoclonal protein (myeloma ...
... and primary lymph node plasmacytoma. Due to the rarity of iMCD, data regarding treatment is limited and based on a combination ...
... plasmacytoma. Bob Wade, 92, American crime writer. Wang Zhongcheng, 86, Chinese academic. Jonathan Wentz, 21, American ...
Cutaneous B-cell lymphoma Multiple myeloma Plasmacytoma Skin lesion James, William D.; Berger, Timothy G.; et al. (2006). ...
He died of plasmacytoma, a rare form of leukemia in 1999 in Berlin. His disease may have been caused by deliberate radioactive ...
To avoid the misdiagnosis of a PCG as a plasmacytoma, it should be noted PCGs are formed from typical plasma cells while ... If instead, results show monoclonality of plasma cells it is indicative of plasmacytoma. The clonality of plasma cells is most ... Occasionally, plasma cell granulomas are misdiagnosed as malignant lymphoma or malignant plasmacytoma during initial ...
"Ligand-Induced Redistribution and Augmentation of Surface-Bound Myeloma Protein on MOPC315 Plasmacytoma Cells". Scandinavian ...
Yan J, Wang J, Zhang W, Chen M, Chen J, Liu W (April 2017). "Solitary plasmacytoma associated with Epstein-Barr virus: a ... EBER-positive patients with the localized plasmacytoma form of PCM are more likely to progress to the infiltrative (i.e. ... The disorder has been treated with surgical removal in cases with one or two isolated plasmacytoma masses, radiation to ... EBV positivity is more common in the plasmacytoma rather than bone marrow infiltration form of PCM. Tissues involved in EBV+ ...
Du Bois was diagnosed with plasmacytoma, a cancer of the immune system, in 2010. He underwent successful therapy, but the ...
He passed away in a house in Ames, Iowa, as a consequence of a plasmacytoma. Fuchs worked on the theory of the optical ...
Plasmacytoma, multiple myeloma, Waldenström macroglobulinemia, heavy chain disease, and plasma cell leukemia are cancers of the ...
The rabbit formed a myeloma-like tumor, allowing the isolation of a plasmacytoma cell line, named 240E-1. Fusion of 240E-1 ...
... and plasmacytoma. Due to the rarity of the disease, data regarding treatment is limited to observational case series and case ...
Prior diagnosis of plasma cell lymphoma (i.e. multiple myeloma or plasmacytoma), the presence of lytic bone lesions, increased ... The other lymphoid neoplasms within this subgroup are: plasmablastic plasma cell lymphoma (or the plasmacytoma variant of this ...
... in vitro killing effectiveness in a mouse plasmacytoma cell model". Cancer Research. 49 (20): 5497-504. PMID 2790777. Lefkowitz ...
... oncogene (non-protein coding), also known as PVT1 or Plasmacytoma Variant Translocation 1 is a long non-coding RNA gene. ... Millis MP, Bowen D, Kingsley C, Watanabe RM, Wolford JK (December 2007). "Variants in the plasmacytoma variant translocation ...
... due to cold gelation of the blood by gamma-plasmacytoma]. Archiv für Klinische und Experimentelle ...
Myeloma Plasmacytoma Lymphoplasmacytic lymphoma Idiopathic (no discernible cause): some of these will be revealed as leukemias ...
As a specialist in otorhinolaryngology, he presented his thesis, Contribution to the study about Plasmacytoma of the upper ...
Patients with one or two plasmacytoma bone lesions and no clonal plasma cells in their bone marrow biopsy specimens are treated ... 2 plasmacytoma bone lesions and/or increases in bone marrow clonal plasma cells are treated with a low-dose or high-dose ...
Primary cutaneous follicular lymphoma Primary cutaneous marginal zone lymphoma Intravascular large B-cell lymphoma Plasmacytoma ...
Plasmacytoma Plasmacytosis Pleomorphic T-cell lymphoma (non-mycosis fungoides CD30− pleomorphic small/medium-sized cutaneous T- ...
... monoclonal gammopathy of undetermined significance Plasma cell myeloma Solitary plasmacytoma of bone Extraosseous plasmacytoma ...
"Guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary ... The International Myeloma Working Group lists three types: solitary plasmacytoma of bone (SPB); extramedullary plasmacytoma (EP ... "solitary plasmacytoma". or as part of the phrase "extramedullary plasmacytoma". In this context, "extramedullary" means outside ... 1 ratio for extramedullary plasmacytoma. There can be some ambiguity when using the word. "Plasmacytoma" is sometimes equated ...
Soft-tissue or nonosseous extramedullary plasmacytoma (EMP) Solitary bone plasmacytoma (SBP) Multifocal form of multiple ... A plasmacytoma is a discrete, solitary mass of neoplastic monoclonal plasma cells in either bone or soft tissue (extramedullary ... Solitary plasmacytoma (SP) has an annual incidence of less than 450 cases in the United States. [2] Solitary bone plasmacytoma ... A plasmacytoma can arise in any part of the body. A solitary bone plasmacytoma (SBP) arises from the plasma cells located in ...
ICD-10 code C90.2 for Extramedullary plasmacytoma is a medical classification as listed by WHO under the range -Malignant ... ICD-10-CM Code for Extramedullary plasmacytoma C90.2 ICD-10 code C90.2 for Extramedullary plasmacytoma is a medical ... Extramedullary plasmacytoma C90. Excludes1: personal history of other malignant neoplasms of lymphoid, hematopoietic and ...
If your doctor misdiagnosed or failed to diagnose plasmacytoma or myeloma in you or a loved one, you could have grounds for a ... Plasmacytoma & Multiple Myeloma Misdiagnosis Lawyer. If your doctor misdiagnosed or failed to diagnose plasmacytoma or myeloma ... Plasmacytoma and myeloma have many signs and symptoms. It is part of your doctors duty of care to recognize these symptoms and ... The plasmacytoma and myeloma misdiagnosis lawyers at Newsome , Melton can help you hold the doctor accountable who caused you ...
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myelom: incidence and survival in the United States, 1992-2004 ... Guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary ... Segmental colectomy is appropriate for colonic plasmacytoma. Surgical excision is ideal for rectal plasmacytoma, with ... Primary plasmacytoma of the gastrointestinal tract is even rarer, occurring in approximately 10% of cases.2 All the segments of ...
... is an isolated plasmacytoma of bone origin, most commonly seen in the elderly, with a poor prognosis. So far, there is no ... i,Background,/i,. Solitary plasmacytoma of bone (SPB) ... Solitary plasmacytoma of bone (SPB) is an isolated plasmacytoma ... Solitary plasmacytoma of bone is a type of malignant plasmacytoma disease with a rare nature and a relatively high recurrence ... Plasmacytomas include extramedullary plasmacytoma (EMP), solitary plasmacytoma of bone (SBP), and multiple myeloma (MM) [1]. ...
Extramedullary plasmacytoma, also known as extraosseous plasmacytoma, are the less common form of solitary plasmacytoma, ... Prognosis for extramedullary plasmacytoma is considered better than for solitary bone plasmacytoma 4,5. ... solitary plasmacytoma overall represent only 3-6% of all plasma cell disorders (i.e. multiple myeloma, plasma cell leukemia) 4 ... A plasmacytoma lesion is composed of monoclonal plasma cells arranged in clusters or sheets. In contradistinction to MM, ...
There is 1 clinical trial for extraosseous plasmacytoma, of which 1 is open and 0 are completed or closed. Of the trial that ... Carfilzomib, dexamethasone, and lenalidomide are the most common interventions in extraosseous plasmacytoma clinical trials. ... contains extraosseous plasmacytoma as an inclusion criterion, 1 is no phase specified (1 open). ...
This case highlights a rare presentation of an extraosseous plasmacytoma within the female genital tract and to our knowledge ... Extraosseus plasmacytoma is rare within the female genital tract. Here, we report the case of a 55 year-old female with a ... is the first reported case of a plasmacytoma involving a leiomyoma. ... Extraosseus plasmacytoma is rare within the female genital tract. Here, we report the case of a 55 year-old female with a ...
Disclaimer: MushroomsGuide.com is an information site ONLY and the focus of this site is on the medicinal mushrooms. Any mushroom, substance or product mentioned on this site are not to be used as a substitute for medical advice, diagnosis or treatment of any health condition or problem, nor as any marketing or sales efforts of any products. Visitors of this site should not solely rely on information provided on this website for their own health problems. The information presented here should only be used as a reference. Any questions regarding your own health should be addressed to your own physician or other health care provider.. ...
N2 - Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma ... AB - Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma ... Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells ... abstract = "Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal ...
The information provided on this website does not provide or should be considered medical advice. It is not a substitute for diagnosis or treatment of any condition. The information provided is for informational purposes only. You should not rely solely on the information provided on this website in making a decision to pursue a specific treatment or advice. You should consult directly with a professional healthcare provider.. As a condition of using the information on this website, Spineopedia.com and its physicians are not responsible for any advice, diagnosis, treatment or outcome you may obtain.. Spineopedia.com is completely self-funded. No outside funds are accepted or used. This website does not utilize paid advertising as a source of revenue.. Last modified: September 20, 2023. ...
... On-line free medical diagnosis assistant. Ranked list of possible diseases from either several ... Ranked list of diseases related to "plasmacytoma"Drugs, active principles and "plasmacytoma"Medicinal plantsQuestions and ... Plasmacytoma (Plasma Cell Tumor). Any discrete, presumably solitary, mass of neoplastic plasma cells either in bone marrow or ...
Plasmacytoma. The 2003 International Myeloma Working Group in classified plasmacytomas as solitary plasmacytoma of bone (SBP) ... Radiotherapy (RT) of soft-tissue plasmacytoma is the further treatment choice and resulted in a high rate of local control and ... Dattolo P, Allinovi M, Michelassi S, Pizzarelli F. Multiple solitary plasmacytoma with multifocal bone involvement. First ... when a solitary soft-tissue lesion was present and multiple solitary plasmacytoma (MSP) when multiple sites of disease were ...
Solitary plasmacytoma. In solitary plasmacytoma, abnormal plasma cells are found to be concentrated in a single tumor called a ... In some cases, a plasmacytoma may be cured. However, solitary plasmacytoma can often develop into multiple myeloma. About 65 to ... plasmacytoma. This condition is rare, making up only about 2 to 5 percent. of all plasma cell disorders. ... 2017). Solitary plasmacytoma.. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584766/. ...
... solitary osseous plasmacytoma (SOP), to one extramedullary area - extramedullary plasmacytoma (EMP), or may, in the case of ... Plasmacytoma is characterized by a monoclonal neoplastic proliferation of plasma cells and the course of the disease may be ... This article describes a case of solitary osseous plasmacytoma of the jaw diagnosed at an early stage in a 63-year-old patient ... Solitary plasmacytoma of the mandible: a case report. Rev. cir. traumatol. buco-maxilo-fac. [online]. 2012, vol.12, n.3, pp. 67 ...
Short, S. R. P., Cook, S. L., Kim, A. S., Lamour, J. M., Lowe, E. J., & Petersen, W. C. (2016). Plasmacytoma-like ... Plasmacytoma-like posttransplant lymphoproliferative disorder in a pediatric heart transplant recipient. Sara Rhodes Proctor ... Plasmacytoma-like posttransplant lymphoproliferative disorder in a pediatric heart transplant recipient. Journal of Pediatric ... Plasmacytoma-like posttransplant lymphoproliferative disorder in a pediatric heart transplant recipient. In: Journal of ...
Solitary bone plasmacytoma of the maxilla - a rare case report. Int J Clin Dent Sci. 2011;2:37-40.. 16 Baad R, Kapse SC, Rathod ... Solitary bone plasmacytoma of the maxilla- a rare case report. Int J Clin Dent Sci. 2011;2:37-40.. 10 Pisano JJ, Coupland R, ... Solitary plasmacytoma of mandible: an unusual bilateral presentation Sandip Kulkarni; Jashika Adil Shroff; SM Meghana; Pournima ... Plasmacytoma of the oral cavity and jaws: a clinicopathological study of 13 cases. Oral Surg Oral Med Oral Pathol Oral Radiol ...
... plasmacytoma cancer , plasmacytoma dog , plasmacytoma icd 10 , plasmacytoma radiology , plasmacytoma treatment , plasmacytoma ... There are two types of plasmacytomas - solitary plasmacytoma of bone (SPB) and extramedullary plasmacytoma (EMP). Plasmacytoma ... Search Results related to plasmacytoma on Search Engine. * Plasmacytoma: What it Is, Treatment, Symptoms & Types - Cleveland ... Plasmacytoma - Wikipedia wikipedia.org. https://en.wikipedia.org/wiki/Plasmacytoma. WebHematology and oncology. Plasmacytoma is ...
Extramedullary Plasmacytoma of the Tonsil. Kevin C. Huoh , Annemieke Van Zante , David W. Eisele ...
Rahman, E. Z., Barros Palau, A. E., Morgan, M. L., & Lee, A. G. (2016). Neuro-ophthalmic presentations of clival plasmacytoma. ... Rahman, EZ, Barros Palau, AE, Morgan, ML & Lee, AG 2016, Neuro-ophthalmic presentations of clival plasmacytoma, Canadian ... Neuro-ophthalmic presentations of clival plasmacytoma. Effie Z. Rahman, Angelina Espino Barros Palau, Michael L. Morgan, Andrew ... Neuro-ophthalmic presentations of clival plasmacytoma. In: Canadian Journal of Ophthalmology. 2016 ; Vol. 51, No. 2. pp. e49- ...
Taken together, this is an IgA plasmacytoma, a recently reported indolent and distinct form of extramedullary plasmacytoma. ... Category: Lymphoma: Mature B-cell and Plasma cell Neoplasms > Plasma Cell Neoplasm > Plasmacytoma > Extraosseous plasmacytoma. ... Recognizing this form of plasmacytoma is of paramount importance to avoid unnecessary treatment. As in this case, the patient ...
Iris plasmacytoma is rare and should prompt systemic evaluation to rule out multiple myeloma. Solitary iris plasmacytoma can be ... Solitary Iris Plasmacytoma With Anterior Chamber Crystalline Deposits. Andrew W Stacey, Alenka Lavric, Caroline Thaung, Samreen ... To report a case of solitary iris plasmacytoma successfully treated with ruthenium plaque radiotherapy. A 44-year-old white ... The monoclonal plasma cell infiltrate was consistent with a solitary iris plasmacytoma. The mass was treated with ruthenium ...
First Reported Case of Extramedullary Plasmacytoma of the Appendix ...
Solitary extramedullary plasmacytoma of the bladder: A case report and literature. Waseem Khaliq, Ikechukwu Uzoaru, Ronald P. ... Solitary extramedullary plasmacytoma of the bladder : A case report and literature. In: ONCOLOGY. 2010 ; Vol. 24, No. 9. ... Solitary extramedullary plasmacytoma of the bladder: A case report and literature. / Khaliq, Waseem; Uzoaru, Ikechukwu; ... Although solitary extramedullary plasmacytoma (SEP) may arise in any organ, it rarely involves the urinary bladder. A 67-year- ...
... SARTORIS, Silvia; ... to assess in a mouse plasmacytoma model the efficacy of this approach towards neoplastic plasma cells. We found that IFN-alpha ... to assess in a mouse plasmacytoma model the efficacy of this approach towards neoplastic plasma cells. We found that IFN-alpha ...
Plasmacytoma. Plasmacytoma of Small Bowel. Plasmacytoma. Lymphoid Hyperplasia. Lymphoid Hyperplasia (Pseudolymphoma). Lymphoid ...
Isolated plasmacytoma involving the brain parenchyma and cerebral spinal fluid, Blood, Volume 122, Issue 1, 4 July 2013, Pages ... Isolated plasmacytoma involving the brain parenchyma and cerebral spinal fluid Qin Huang Qin Huang ... Qin Huang; Isolated plasmacytoma involving the brain parenchyma and cerebral spinal fluid. Blood 2013; 122 (1): 6. doi: https ... The tumor cells were positive for CD138 and CD56 with λ light chain restriction, consistent with plasmacytoma. The ...
Extraosseous plasmacytoma * Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma ...
Plasma cell dyscrasia; Plasma cell myeloma; Malignant plasmacytoma; Plasmacytoma of bone; Myeloma - multiple ...
  • extramedullary plasmacytoma (EP), and multiple plasmacytomas that are either primary or recurrent. (wikipedia.org)
  • SPBs and extramedullary plasmacytomas are mostly treated with radiotherapy, but surgery is used in some cases of extramedullary plasmacytoma. (wikipedia.org)
  • Surgery is an option for extramedullary plasmacytoma, but for cosmetic reasons it is generally used when the lesion is not present within the head and neck region. (wikipedia.org)
  • 30-50% of extramedullary plasmacytoma cases progress to multiple myeloma with a median time of 1.5-2.5 years. (wikipedia.org)
  • 15-45% of SPB and 50-65% of extramedullary plasmacytoma are disease free after 10 years. (wikipedia.org)
  • with a 2:1 male to female ratio for SPB and a 3:1 ratio for extramedullary plasmacytoma. (wikipedia.org)
  • Guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas: 2009 update" (PDF). (wikipedia.org)
  • A solitary bone plasmacytoma (SBP) arises from the plasma cells located in the bone marrow, whereas an extramedullary plasmacytoma (EMP) is thought to arise from plasma cells located in mucosal surfaces. (medscape.com)
  • [ 5 ] Both SBP and extramedullary plasmacytoma (EMP) do, however, share many of the biologic features of other plasma cell disorders. (medscape.com)
  • 80%), the etiology of extramedullary plasmacytoma (EMP) may be related to chronic stimulation of inhaled irritants or viral infection. (medscape.com)
  • [ 11 ] In the United States during 2003‐2016, overall incidence rates in adults were 0.45 per 100,000 persons for SP and 0.09 per 100,000 persons for extramedullary plasmacytoma. (medscape.com)
  • Plasmacytomas include extramedullary plasmacytoma (EMP), solitary plasmacytoma of bone (SBP), and multiple myeloma (MM) [ 1 ]. (hindawi.com)
  • Solitary extramedullary plasmacytoma (SEP) is a neoplastic proliferation of a single clone of plasma cells that occur outside of the bone and bone marrow. (scielo.org.za)
  • To our knowledge, this is the first reported case of extramedullary plasmacytoma of the colon and rectum in association with HIV infection. (scielo.org.za)
  • Extramedullary plasmacytoma , also known as extraosseous plasmacytoma , are the less common form of solitary plasmacytoma , manifesting as isolated plasma cell tumors located at a non-osseous site. (radiopaedia.org)
  • Non-specific symptoms such as pain caused by local mass effect and compression of the surrounding organs by the extramedullary plasmacytoma 7 . (radiopaedia.org)
  • Prognosis for extramedullary plasmacytoma is considered better than for solitary bone plasmacytoma 4,5 . (radiopaedia.org)
  • Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. (amsterdamumc.org)
  • There are two types of plasmacytomas - solitary plasmacytoma of bone (SPB) and extramedullary plasmacytoma (EMP). (websiteperu.com)
  • WebA plasmacytoma is a discrete, solitary mass of neoplastic monoclonal plasma cells in either bone or soft tissue (extramedullary). (websiteperu.com)
  • Plasmacytoma is characterized by a monoclonal neoplastic proliferation of plasma cells and the course of the disease may be confined to one medullary area of the bone - solitary osseous plasmacytoma (SOP), to one extramedullary area - extramedullary plasmacytoma (EMP), or may, in the case of multiple myeloma, involve many areas. (bvsalud.org)
  • Plasmacytoma is a neoplastic proliferation of monoclonal plasma cells, which can present clinically as solitary bone neoplasm, extramedullary plasmacytoma, and multiple myeloma. (autopsyandcasereports.org)
  • Taken together, this is an IgA plasmacytoma, a recently reported indolent and distinct form of extramedullary plasmacytoma.Recognizing this form of plasmacytoma is of paramount importance to avoid unnecessary treatment. (hematology.org)
  • Although solitary extramedullary plasmacytoma (SEP) may arise in any organ, it rarely involves the urinary bladder. (johnshopkins.edu)
  • IJROBP Journal SA-CME activity for July 15, 2018 (Volume 101, Issue 4) provides radiation oncologists with evidence based guidelines in the management of Solitary Bone Plasmacytoma and Solitary Extramedullary Plasmacytoma and Multiple Myeloma. (astro.org)
  • Extramedullary plasmacytoma is a rare plasma cell neoplasm that arises most frequently in the head and neck and mainly involves the sinonasal or nasopharyngeal regions. (journalmc.org)
  • We describe a 68-year-old patient who developed an extramedullary plasmacytoma coexisting with fungus balls in the paranasal sinuses and was initially treated as fungal sinusitis. (journalmc.org)
  • Multifocal Extramedullary and Multiple Solitary Bone Plasmacytoma: A Case R. (brieflands.com)
  • Solitary bone plasmacytoma and extramedullary plasmacytoma are the proliferation of plasma cells in bone or soft tissues, without bone marrow involvement or other systemic presentation of multiple myeloma. (brieflands.com)
  • Multiple extramedullary plasmacytoma or multiple solitary plasmacytoma is defined as when there is more than one extramedullary tumor of plasma cells or multiple sites of disease in bone. (brieflands.com)
  • We report such rare case of multiple extramedullary plasmacytoma involving skin and soft tissues of abdomen wall, pelvic, chest, and solitary plasmacytoma bone in rib 6 chest and in bone of sacrum also diagnostic work up, treatment and care to the patients we have done. (brieflands.com)
  • Plasmacytoma have 2 clinical presentations, including solitary plasmacytoma of bone and extramedullary plasmacytoma. (brieflands.com)
  • The evaluation of a patient with a lesion suspected to solitary plasmacytoma or extramedullary plasmacytoma, whose diagnosis was confirmed after tissue biopsy, include a complete history and physical examination and a biochemical profile screen that consists of measurements of complete blood count and differential, biochemical values, beta-2 microglobulin, protein electrophoresis, quantification of immunoglobulins, and serum-free monoclonal light chain. (brieflands.com)
  • In diagnostic criteria for extramedullary plasmacytoma, no other osteolytic bone lesions is added ( 3 ). (brieflands.com)
  • Clinical outcome of extramedullary plasmacytoma. (najms.com)
  • Dimopoulos MA, Kiamouris C, Moulopoulos LA. Solitary plasmacytoma of bone and extramedullary plasmacytoma. (najms.com)
  • Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. (najms.com)
  • Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. (najms.com)
  • Extramedullary plasmacytoma in the head and neck: a report of 10 cases and literature review. (najms.com)
  • Solitary plasmacytoma (SP) is an early-stage plasma cell malignancy that is in between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) along the spectrum of plasma cell disorders. (medscape.com)
  • For patient education information, see the Multiple Myeloma Health Center and What is solitary plasmacytoma? . (medscape.com)
  • If your doctor misdiagnosed or failed to diagnose plasmacytoma or myeloma in you or a loved one, you could have grounds for a medical malpractice lawsuit. (medicalmalpracticehelp.com)
  • Plasmacytoma and multiple myeloma are cancers of the plasma cells. (medicalmalpracticehelp.com)
  • They often occur together, with myeloma leading to plasmacytoma tumors growing within the soft tissue or bony skeleton. (medicalmalpracticehelp.com)
  • Plasmacytoma and myeloma have many signs and symptoms. (medicalmalpracticehelp.com)
  • Moreover, certain characteristics involving your age, race, gender, and lifestyle increase your risk of developing plasmacytoma or myeloma. (medicalmalpracticehelp.com)
  • If your doctor misdiagnosed or failed to diagnose your plasmacytoma or myeloma, it may mean they either did not notice that you had signs pointing to the condition, or did notice but failed to follow up on it. (medicalmalpracticehelp.com)
  • The presence of more symptoms along with one or more risk factors indicates an even more urgent need to test for plasmacytoma and myeloma right away. (medicalmalpracticehelp.com)
  • Melton, our plasmacytoma and myeloma misdiagnosis lawyers understand that the success of your medical malpractice case rests on the strength of the evidence we are able to collect and assemble. (medicalmalpracticehelp.com)
  • However, solitary plasmacytoma can often develop into multiple myeloma. (healthline.com)
  • Plasmacytoma is similar to multiple myeloma. (websiteperu.com)
  • 12 Di Micco P, Di Micco B. Update on solitary plasmacytoma and its main differences with multiple myeloma. (autopsyandcasereports.org)
  • Plasmacytoma is a rare B-lymphocyte neoplastic disorder that usually presents as the generalized disease multiple myeloma. (johnshopkins.edu)
  • These findings might be solitary or, more commonly, associated with multiple myeloma (MM). Nearly 7.0% of MM cases present a plasmacytoma at the time of diagnosis. (com.pt)
  • Discuss updated data and guidelines for treatment options for multiple myeloma and plasmacytoma. (astro.org)
  • Describe recommended radiotherapy doses and fields for multiple myeloma and plasmacytoma for palliative and definitive cases. (astro.org)
  • Perform appropriate workup and discuss treatment options and post-treatment follow-up for multiple myeloma and plasmacytoma. (astro.org)
  • These characteristics were consistent with a diagnosis of plasmacytoma, excluding the possibility of multiple myeloma (MM). (biomedcentral.com)
  • Our case of IgA-secreting plasmacytoma confirms the results of the authors generally, with multiple lymph node lesions, an lack of development to multiple myeloma, and plasmacytoma advancement against a history from the long-term span of SS. (irpa2006europe.com)
  • The International Myeloma Working Group in 2003 has recognized a separate classification of plasmacytomas that occurs as multiple sites of disease in soft tissue, bone, or both soft tissue and bone as multiple solitary plasmacytoma ( 4 ). (brieflands.com)
  • Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study. (najms.com)
  • Context Radiotherapy is the treatment of first choice in bone lesions of plasmacytoma or multiple myeloma (MM). Nevertheless, large bone lesions often completely disrupt the bone structure, jeopardize stability, and thus are considered to enforce stabilization by surgical interventions. (thieme-connect.com)
  • This form of treatment can be used with curative intent because plasmacytoma is a radiosensitive tumor. (wikipedia.org)
  • In solitary plasmacytoma, abnormal plasma cells are found to be concentrated in a single tumor called a plasmacytoma. (healthline.com)
  • WebJul 31, 2023 · Plasmacytoma is a tumor of plasma cells of bony or soft tissue and can occur anywhere in the body without evidence of systemic disease. (websiteperu.com)
  • WebJun 29, 2022 · Plasmacytoma is a tumor of the plasma cells found in bone or soft tissues of the body. (websiteperu.com)
  • 13 Rezaei F, Nazari H, Izadi B. Solitary plasmacytoma in the mandible resembling an odontogenic cyst/tumor. (autopsyandcasereports.org)
  • The tumor cells were positive for CD138 and CD56 with λ light chain restriction, consistent with plasmacytoma. (ashpublications.org)
  • Solitary plasmacytoma is a rare malignant tumor , presenting less than 5% of all plasma cell proliferation. (bvsalud.org)
  • There is 1 clinical trial for extraosseous plasmacytoma, of which 1 is open and 0 are completed or closed. (mycancergenome.org)
  • Of the trial that contains extraosseous plasmacytoma as an inclusion criterion, 1 is no phase specified (1 open). (mycancergenome.org)
  • Carfilzomib, dexamethasone, and lenalidomide are the most common interventions in extraosseous plasmacytoma clinical trials. (mycancergenome.org)
  • This case highlights a rare presentation of an extraosseous plasmacytoma within the female genital tract and to our knowledge is the first reported case of a plasmacytoma involving a leiomyoma. (dtic.mil)
  • Multiple solitary plasmacytomas may be developing over time in approximately 5% of the patients with apparently solitary plasmacytoma. (brieflands.com)
  • Solitary plasmacytoma of bone (SPB) is a rare localized neoplasm that accounts for only 5 % of malignant plasma cell tumors [ 1 ]. (biomedcentral.com)
  • A phenotypically dominant regulatory mechanism suppresses major histocompatibility complex class II gene expression in a murine plasmacytoma. (ox.ac.uk)
  • We have studied the mechanism of down-regulation of MHC class II expression in a BALB/c strain-derived murine plasmacytoma cell line, NS1. (ox.ac.uk)
  • Since NS1 is a subclone of the P3-X63Ag8 murine plasmacytoma, we also tested one P3-X63Ag8 x splenic B cell hybrid, Sp2/0, and two Sp2/0 x splenic B cell hybrids. (ox.ac.uk)
  • A novel 6:10 chromosomal translocation in the murine plasmacytoma ns-1" by R M. Perlmutter, J L. Klotz et al. (jax.org)
  • A novel 6:10 chromosomal translocation in the murine plasmacytoma ns-1. (jax.org)
  • We present the case of solitary plasmacytoma of the mandible with rare bilateral involvement in a 65-year-old female patient. (autopsyandcasereports.org)
  • 1 Sharma NK, Singh AK, Pandey A, Verma V. Solitary plasmacytoma of the mandible: a rare case report. (autopsyandcasereports.org)
  • Solitary plasmacytoma of mandible: a rare entity. (autopsyandcasereports.org)
  • Unusual presentation of solitary plasmacytoma of mandible with review of literature. (autopsyandcasereports.org)
  • We report a case of 65 years old female patient with solitary bone plasmacytoma of mandible , who has undergone surgical treatment without adjuvant therapy , with a good clinical and radiological outcomes at 12 months follow-up. (bvsalud.org)
  • Conclusions Currently, principal lymph node plasmacytoma is normally regarded a nodal marginal area lymphoma with a thorough plasmacytic differentiation. (irpa2006europe.com)
  • A plasmacytoma lesion is composed of monoclonal plasma cells arranged in clusters or sheets. (radiopaedia.org)
  • Magnetic Resonance Imaging (MRI) revealed two and a half and 3cm length cranial lesion, which proved to be plasmacytoma. (edu.pl)
  • However, in this full case, the Rabbit Polyclonal to Involucrin lymph node lesion was exhibited and generalized no proof upper respiratory system plasmacytoma. (irpa2006europe.com)
  • IL-6 synonyms: plasmacytoma growth factor (PCT-GF),interferon-a-2 (IFN-a2), monocyte derived human B cellgrowth factor, B cell stimulating factor (BSF-2),hepatocyte stimulating factor (HSF), and interleukinhybridoma/plasmacytoma-1 (IL-HP1). (abcam.com)
  • Solitary plasmacytoma of bone (SPB) is an isolated plasmacytoma of bone origin, most commonly seen in the elderly, with a poor prognosis. (hindawi.com)
  • SEP usually carries a better prognosis and higher cure rate than solitary plasmacytoma of bone, as SEP is radiation sensitive. (johnshopkins.edu)
  • [ 1 ] A plasmacytoma is a discrete, solitary mass of neoplastic monoclonal plasma cells. (medscape.com)
  • Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission. (johnshopkins.edu)
  • Given the clinical findings, the diagnosis of MM with an associated thoracic plasmacytoma was established. (com.pt)
  • Discussion: In this case, the most relevant clinical finding is the thoracic plasmacytoma. (com.pt)
  • Herein, we report a case of solitary plasmacytoma of the rib (SPR) with unique clinical features. (biomedcentral.com)
  • An 18-season follow-up of our individual with principal lymph node plasmacytoma confirmed an exceptionally unusual clinical training course. (irpa2006europe.com)
  • Solitary intracranial plasmacytoma (SIP) is a rare entity. (najms.com)
  • Solitary intracranial plasmacytoma located in the spheno-clival region mimicking chordoma: a case report. (najms.com)
  • This article describes a case of solitary osseous plasmacytoma of the jaw diagnosed at an early stage in a 63-year-old patient and treated with 25 sessions of radiotherapy totaling 45 Gy. (bvsalud.org)
  • The immunostaining pattern was consistent with plasmacytoma. (najms.com)
  • Anaplastic Thyroid Carcinoma Histologically Mimicking a Plasmacytoma. (nih.gov)
  • WebApr 15, 2022 · A plasmacytoma is an abnormal growth of a type of white blood cell called a plasma cell. (websiteperu.com)
  • The patient underwent complete en-bloc resection of the chest wall, including the ribs, muscle, and parietal pleura. (biomedcentral.com)
  • Plasmacytoma is a plasma cell dyscrasia in which a plasma cell tumour grows within soft tissue or within the axial skeleton. (wikipedia.org)
  • Solitary bone plasmacytoma are treated surgically with or without adjuvant radiation, although now, definitive radiation therapy is the treatment of choice ( 5 ). (brieflands.com)
  • Plasmacytoma is a primary and systemic malignancy originating from the bone marrow and characterized by clonal proliferation of plasma cells. (hindawi.com)
  • The literature also lacks recommendations for choice of a chemotherapy regimen and surveillance of isolated bladder plasmacytoma. (johnshopkins.edu)
  • Initially, principal lymph node plasmacytoma was refractory to chemotherapy. (irpa2006europe.com)
  • WebFind symptoms and other information about Plasmacytoma. (websiteperu.com)
  • Regardless of the absence of following adequate therapy, she achieved complete remission of plasmacytoma using the disappearance of paraproteins gradually. (irpa2006europe.com)
  • In this review, a panel of expert European hematologists updates the recommendations on the diagnosis and management of patients with solitary plasmacytoma. (amsterdamumc.org)
  • Here, we present a rare report of a plasmacytoma-like PTLD case in a pediatric heart transplant recipient. (elsevierpure.com)
  • 4 Kamal M, Kaur P, Gupta R, Gupta S, Singh S. Mandibular plasmacytoma of jaw-a case report. (autopsyandcasereports.org)
  • 6 Lesmes D, Laster Z. Plasmacytoma in the temporomandibular joint: a case report. (autopsyandcasereports.org)
  • Instead, this case portraits a thoracic plasmacytoma associated with MM. Most likely, this complication is the result of the natural progression of MGUS. (com.pt)
  • We present the case of a 44-year-old Han Chinese man who was diagnosed with a solitary plasmacytoma of the bone located in the right sixth rib. (biomedcentral.com)
  • Although plasmacytoma more commonly occur within bone , they may also occur in other organs throughout the body. (radiopaedia.org)
  • Solitary plasmacytoma (SP) has an annual incidence of less than 450 cases in the United States. (medscape.com)
  • Primary plasmacytoma of the gastrointestinal tract is even rarer, occurring in approximately 10% of cases. (scielo.org.za)
  • In some cases, a plasmacytoma may be cured. (healthline.com)
  • Although more common in adults, 8 cases of plasmacytoma-like PTLD have been reported in pediatric renal and combined small bowel-liver transplant recipients. (elsevierpure.com)
  • [ 2 ] Solitary bone plasmacytoma (SBP) affects fewer than 5% of patients with plasma cell disorders. (medscape.com)
  • The literature reviewed showed the solitary bone plasmacytoma consisting of 2% to 5% of plasma cell dyscrasias evaluated at referral centers. (brieflands.com)
  • In 1999, Hussong and/or gene rearrangements in PCR evaluation in mere 64% (7/11) from the situations of plasmacytoma, regardless of the obvious light string restriction discovered by immunohistochemistry [4]. (irpa2006europe.com)